Germany's Dermapharm will pay €450m to acquire herbal specialist Arkopharma to expand its footprint in Europe's consumer health market in countries such as France, Spain and Italy.

The global market leader in consumer health is now Haleon following its separation from GSK after more than two years of planning.

France's Mayoly Spindler is expanding its offering in its local dietary supplements market by acquiring Pharm Nature Micronutrition which specializes in natural products based on organic ingredients.

Vision Healthcare’s Sensilab pulled Facebook advertisements for its weight loss supplements after UK regulator the Advertising Standards Authority launched an investigation into whether the marketing, which featured slim models, was "irresponsible." 

Heerlen, Netherlands-based DSM posted a double-digit rise in sales at its Health, Nutrition and Care operation in the first half despite facing a "continuous battle" to place and receive deliveries.

Members led by SC Republican Jeff Duncan and CA Democrat Tony Cárdenas, in letter to House speaker and minority leader, oppose MPL provision in latest version of S.4348 for re-authorizing FDA drug, biologic and medical device user fee programs.

Heerlen, Netherlands-based DSM posted a double-digit rise in sales at its Health, Nutrition and Care operation in the first half despite facing a "continuous battle" to place and receive deliveries.

OTC drug and dietary supplement companies continue to face significant economic and competitive issues in what continues to be a highly volatile operating environment. Here we’ve culled takes from top execs at Sanofi, Bayer, J&J, P&G and other leading players, provided during recent sales and earnings presentations.

Along with Q2 results including reported net sales up 14.3% to $1.12bn, Perrigo announces overhaul of its supply chain expected to generate $100m to $300m in net cost savings and creation of women's health, skin care business units.

Host of complaints in US courts, seeking damages or alleging ranitidine caused various cancers, followed FDA’s 2020 findings of NDMA levels exceeding allowable limits in some samples provoked  Litigation is starting to come to trial, the first set for 22 August in Illinois and a bellwether case due to begin in California in February 2023.

Recent 9th Circuit ruling upheld granting a firm preliminary injunction stopping competitor from using its trademarked brand for delta-8 THC products. Ruling generally runs counter to USPTO policy against accepting trademark registrations for hemp or cannabis products and specifically counters FDA stance delta-8 doesn’t meet definition of hemp under 2018 farm bill.

Reference in report accompanying House Appropriation Committee bill for FDA FY2023 budget isn’t binding and wasn’t appropriators’ first mention of agency’s response to de-scheduling hemp as a controlled substance. But their ’ statement was more pointed than in previous appropriation reports.